No Detail Found!

Synergistic Effects of Omeprazole and Metformin on Glycemic Control in Type 2 Diabetic Patients. a Randomized Clinical Study.

Author(s)
Fizzah Ali Department of Pharmacology & Therapeutics, Basic Medical Sciences Institute Jinnah Postgraduate Medical Centre Karachi, Pakistan
Moosa Khan Basic Medical Sciences Institute Jinnah Postgraduate Medical Centre Karachi, Pakistan
Kausar Aamir Department of Pharmacology & Therapeutics, Basic Medical Sciences Institute Jinnah Postgraduate Medical Centre Karachi, Pakistan
Muhammad Azhar Mughal Basic Medical Sciences Institute Jinnah Postgraduate Medical Centre Karachi, Pakistan
Abstract
Objective: To evaluate the synergistic effects of omeprazole and metformin on glycemic control among patients with type 2 diabetes. Method: This randomized interventional clinical study was conducted in the Department of Pharmacology and Therapeutics, Basic Medical Sciences Institute, Jinnah post graduate medical Centre Karachi. Total study period was 10 months (august 2014-June2015) with individual study period of 3 months (90 days), Eighty(80) type 2 diabetic patients (40 in each group) of either sex, ages ranged from 30 to 60 years without any known comorbidities were included. Group-A was treated with metformin alone and Group-B was treated with metformin plus omeprazole. Efficacy was evaluated by means of FBG, and HbA1C. Results: Out of 80 patients, 74 had completed the study. Group B showed significant reduction (P=0.001) in terms of FBS and HbA1c level when comparison was done on day 90 with Group A and within group as compared to day 0. Conclusion:-Addition of proton pump inhibitor with metformin was found effective in achieving better glycemic control in type 2 diabetic patients.
Publication Details
Page(s) 24-28
DOI DOI not available
Published Journal: Journal of Dow University of Health Sciences, Volume: 11, Issue: 1, Year: 2017

Request the full text from PASTIC

References
PieroMN,NzaroGM,Njagi JM, 2014.Diabetes mellitus a devastating metabolic disorder,Asian J Biomed Pharmaceu Sci 04 1 -7
AnsariRM,DixonJB, 2015.Coles J. Type 2 diabetes: Challenges to health care system of Pakistan,Intern J Diabetes Res 4 7 -12
ForbesJM,Cooper ME, 2013.Mechanisms of diabetic complications,Physiol Rev 93 137 -88
NyenweEA,JerkinsTW,UmpierreGE,KitabchiAE, 2011.Management of type 2 diabetes: Evolving strategies for the treatment of patients with type 2 diabetes,J Metabol 60 1 -23
Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes., -
DiabetesCare, 2013., 36 127 -8
ShinJM,Kim N, 2013.Pharmacokinetics and pharmacodynamics of the proton pump inhibitors,J Neurogasteroenterol Motil 19 25 -35
TakebayashiK,InukaiT., 2015.Effect of proton pump inhibitors on glycemic control in patients with diabetes,World J Diabetes 6 1122 -31
BarchettaI,GuglielmiC,BertocciniL,CalellaD,ManfriniS,SecchiC,PozzilliP,CavalloMG, 2015.Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control,Acta Diabetol 52 873 -80
CrouchMA,MeffordIN,WadeEU, 2012.Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes,J Am Board Fam Med 25 50 -4
., -
InciF,AtmacaM,OzturkM,YildizS,KocerogluR,SekerogluR,IpekciSH,Kebapcilar, 2014.Pantoprazole may improve beta cell function and diabetes mellitus,JEndocrional Invest 37 449 -54
MeffordIN,WadeEU, 2009.Proton pump inhibitors as a treatment method for type II diabetes,Med Hypotheses 73 29 -32
SinghPK,HotaD,DuttaP,SachdevaN,ChakrabartiA,SrinivasanA,SinghI,BhansaliA, 2012.Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial,J Clin Endocrinol Metab 97 2105 -08
BödvarsdóttirTB,HoveKD,GotfredsenCF, 2010.Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes,Diabetologia 53 2220 -23
Boj-CarcellerD,Bocos-TerrazP,MorenoVernisM,Sanz-ParisA,Trincado-AznarP,Albero-GamboaR, 2011.Are proton pump inhibitors a new anti-diabetic drug? A cross sectional study,World J Diabetes 2 217 -20
HanN,OhM,ParkSM,KimYJ,LeeEJ,KimTK,KimTN,KwonMJ,KimMK,LeeSH,RheeBD, 2015.ParkJH.The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type2 diabetes mellitus, 24 -8
KoopH,KleinM,ArnoldR, 1990.Serum gastrin levels during long-term omeprazole treatment,Aliment Pharmacol Ther 4 131 -8
TéllezN,JoannyG,EscorizaJ,VilasecaM,MontanyaE., 2011.Gastrin treatment stimulates -cell regeneration and improves glucose tolerance in 95% pancreatectomized rats,Endocrinology 2 2580 -8
SanakaM,YamamotoT,KuyamaY., 2010.Effects of proton pump inhibitors on gastric emptying: a systematic review,Dig Dis Sci 55 2431 -40
HirstJA,FarmerAJ,DyarA,LungTWC,StevensRJ, 2013.Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis,Diabetologia 56 973 -84
RauTT,SonstA,RoglerA,BurnatG,NeumannH,OecklK,NeuhuberW,DimmlerA,FallerG,BrzozowskiT,HartmannA,KonturekPC, 2013.Gastrin mediated down regulation of ghrelin and its pathophysiological role in atrophic gastritis,J Physiol Pharmacol 64 719 -25
CaoY,CaoX,LiuXM, 2015.Expression of cholecystokinin-2 receptor in rat and human L cells and the stimulation of glucagon-like peptide-1 secretion by gastrin treatment,Acta Histochem 117 205 -21
KimA.,Chung,YoonSH,YuKS,LimKS,ChoJY,LeeH,JangIJ,ChungJY, 2014.Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics,Drug Metab Dispos 42 1174 -9
AntoniouT,MacDonaldEM,HollandsS, 2015.Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study,CMAJ 3 166 -71
XieY,BoweB,LiT, 2016.Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD,J Am Soc Nephrol 27 3153 -
0

Citations

0

Downloads

53

Views